First Heartland Consultants’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.81M Buy
4,010
+245
+7% +$250K 0.31% 79
2026
Q1
$3.46M Buy
3,765
+34
+0.9% +$34.5K 0.27% 86
2025
Q4
$4.01M Buy
3,731
+27
+0.7% +$25.8K 0.3% 78
2025
Q3
$2.83M Sell
3,704
-110
-3% -$81.9K 0.23% 93
2025
Q2
$2.97M Buy
3,814
+31
+0.8% +$24.1K 0.26% 83
2025
Q1
$3.12M Sell
3,783
-48
-1% -$39.9K 0.32% 78
2024
Q4
$2.96M Sell
3,831
-100
-3% -$82.8K 0.3% 72
2024
Q3
$3.48M Sell
3,931
-234
-6% -$210K 0.37% 56
2024
Q2
$3.77K Sell
4,165
-29
-0.7% -$23.2K 0.26% 70
2024
Q1
$3.26M Buy
4,194
+177
+4% +$126K 0.34% 73
2023
Q4
$2.34M Buy
4,017
+67
+2% +$39.1K 0.28% 82
2023
Q3
$2.12M Buy
3,950
+59
+2% +$30.4K 0.27% 88
2023
Q2
$1.82M Buy
3,891
+74
+2% +$31K 0.24% 96
2023
Q1
$1.31M Sell
3,817
-63
-2% -$21.2K 0.2% 112
2022
Q4
$1.42M Buy
3,880
+157
+4% +$55.7K 0.23% 103
2022
Q3
$1.2K Sell
3,723
-292
-7% -$92.5K 0.1% 112
2022
Q2
$1.3M Sell
4,015
-50
-1% -$15K 0.2% 100
2022
Q1
$1.16M Sell
4,065
-207
-5% -$53.3K 0.18% 100
2021
Q4
$1.18K Sell
4,272
-43
-1% -$10.9K 0.05% 102
2021
Q3
$997K Sell
4,315
-522
-11% -$129K 0.15% 133
2021
Q2
$1.11M Buy
4,837
+41
+0.9% +$8.24K 0.17% 128
2021
Q1
$896K Sell
4,796
-546
-10% -$107K 0.14% 138
2020
Q4
$902K Buy
5,342
+131
+3% +$19.6K 0.15% 110
2020
Q3
$771K Sell
5,211
-311
-6% -$48.1K 0.15% 105
2020
Q2
$907K Buy
5,522
+151
+3% +$23.2K 0.18% 107
2020
Q1
$745K Sell
5,371
-529
-9% -$72.7K 0.19% 104
2019
Q4
$775K Sell
5,900
-79
-1% -$9.16K 0.15% 136
2019
Q3
$669K Sell
5,979
-191
-3% -$21.3K 0.14% 135
2019
Q2
$684K Buy
6,170
+474
+8% +$55.8K 0.16% 121
2019
Q1
$739K Buy
5,696
+2,124
+59% +$258K 0.21% 115
2018
Q4
$413K Sell
3,572
-1,323
-27% -$148K 0.15% 132
2018
Q3
$525K Sell
4,895
-191
-4% -$19.1K 0.16% 129
2018
Q2
$434K Sell
5,086
-247
-5% -$20.3K 0.15% 148
2018
Q1
$413K Sell
5,333
-267
-5% -$21.5K 0.12% 176
2017
Q4
$473K Sell
5,600
-778
-12% -$66.2K 0.14% 158
2017
Q3
$546K Sell
6,378
-39
-0.6% -$3.2K 0.13% 203
2017
Q2
$528K Buy
6,417
+155
+2% +$12.6K 0.14% 193
2017
Q1
$527K Sell
6,262
-140
-2% -$11.2K 0.15% 188
2016
Q4
$471K Sell
6,402
-167
-3% -$12.4K 0.14% 182
2016
Q3
$527K Sell
6,569
-189
-3% -$15.1K 0.15% 166
2016
Q2
$532 Sell
6,758
-11
-0.2% -$828 0.06% 150
2016
Q1
$487K Buy
6,769
+37
+0.5% +$2.8K 0.19% 142
2015
Q4
$567K Sell
6,732
-10
-0.1% -$830 0.22% 123
2015
Q3
$564K Buy
6,742
+72
+1% +$6.08K 0.24% 119
2015
Q2
$557 Buy
6,670
+191
+3% +$14.6K 0.15% 128
2015
Q1
$471K Sell
6,479
-49
-0.8% -$3.49K 0.18% 142
2014
Q4
$450K Buy
6,528
+74
+1% +$5K 0.19% 149
2014
Q3
$419K Buy
6,454
+14
+0.2% +$886 0.18% 153
2014
Q2
$400K Buy
6,440
+302
+5% +$18K 0.18% 142
2014
Q1
$361K Sell
6,138
-133
-2% -$7.42K 0.18% 141
2013
Q4
$320K Sell
6,271
-1,252
-17% -$62.7K 0.18% 135
2013
Q3
$381K Sell
7,523
-3,414
-31% -$179K 0.23% 131
2013
Q2
$537K Buy
+10,937
New +$595K 0.31% 87

Other funds holding LLY

First Heartland Consultants's LLY Position: Q2 2026 in Review

First Heartland Consultants increased its Eli Lilly (LLY) stake by 6.5% in Q2 2026, buying an estimated $250K and bringing the position to 4,010 shares worth $4.81M. The position accounts for 0.31% of the portfolio, ranked #79.

First Heartland Consultants first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • First Heartland Consultants held 4,010 shares of Eli Lilly worth $4.81M as of Q2 2026.
  • First Heartland Consultants bought 245 Eli Lilly shares in Q2 2026, an estimated $250K.
  • Eli Lilly made up 0.31% of First Heartland Consultants's portfolio in Q2 2026, its #79 holding.
  • First Heartland Consultants first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on First Heartland Consultants's 13F filing for Q2 2026, filed 8 Jul 2026.